Q-omics provides the consensus-scored MAPK11 profile across patient tissues and cancer cell-line models. MAPK11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAPK11 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MAPK11 RNA expression shows 16,737 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where MAPK11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK11 survival associations across molecular data types. MAPK11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK11 RNA expression–survival associations across cancer types. High MAPK11 expression shows unfavorable associations in ACC, MESO, BLCA and COAD, but favorable associations in ESCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAPK11 RNA expression.
This table summarizes MAPK11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MAPK11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK11 shows lower tumor expression in KIRP and UCEC and higher tumor expression in KIRC, HNSC, LIHC and COAD. The KIRC box plot shows higher MAPK11 RNA expression in tumor versus normal tissue (log2 FC = +1.047, t-test p < 0.001).
This table shows molecular features associated with MAPK11 in patient tissues and cancer cell lines. In patient samples, MAPK11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
